Bausch + Lomb Corporation (BLCO) Earnings
Bausch + Lomb Corporation is expected to report next earnings on July 29, 2026 (in NaN days), with a consensus EPS estimate of $0.16. BLCO has beaten EPS estimates in 8 of its last 12 reported quarters (average surprise +13.5% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 29, 2026 | $0.06 | $0.08 | +33.3% | $1.2B | +2.3% |
| Feb 18, 2026 | $0.35 | $0.32 | -8.6% | $1.4B | +15.5% |
| Oct 29, 2025 | $0.16 | $0.18 | +12.5% | $1.3B | -7.4% |
| Jul 30, 2025 | $0.06 | $0.07 | +16.7% | $1.3B | +0.3% |
| Apr 30, 2025 | $0.03 | $-0.07 | -333.3% | $1.1B | -9.6% |
| Feb 19, 2025 | $0.24 | $0.25 | +4.2% | $1.3B | +11.2% |
| Oct 30, 2024 | $0.16 | $0.17 | +6.3% | $1.2B | -4.7% |
| Jul 31, 2024 | $0.13 | $0.13 | +0.0% | $1.2B | -24.3% |
| May 1, 2024 | $0.09 | $0.07 | -22.2% | $1.1B | -32.1% |
| Feb 21, 2024 | $0.17 | $0.24 | +41.2% | $1.2B | -21.7% |
| Nov 1, 2023 | $0.18 | $0.22 | +22.2% | $1.0B | -26.0% |
| Aug 2, 2023 | $0.16 | $0.18 | +12.5% | $1.0B | +7.6% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · April 29, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
• Bausch & Lomb is a durable growth company with long-term tailwinds in aging populations, rising myopia, and premium products in cataract surgery. • Focused on building a strong foundation, simplifying organization, driving cost discipline, and improving execution. • Pharmaceuticals had 12% constant currency revenue growth and 14% reported growth. • AI is being embedded for operational excellence. • Pipeline progressing with NDA for Lumify Next and CE mark submission for Celera. • Commercialization of Preservision ARADS III and Blink TripleCare. • Vision care segment continues to deliver, contact lens growth a bright spot. • Surgical business impacted by temporary factors but taking action to strengthen competitive position. • Premium strategy gaining traction with increased premium product mix.
Guidance
• Raised full-year revenue guidance to $5.42 billion to $5.52 billion, reflecting constant currency growth of approximately 5.3% to 7.2%. • Raised full-year adjusted EBITDA guidance to $1.01 billion to $1.06 billion, with margin of approximately 19% and adjusted EBITDA growth of approximately 16% year-over-year. • Estimates currency tailwinds of approximately $50 million to revenue. • Expect adjusted gross margin to be approximately 62% and R&D investments to be 7.5% to 8% of revenue. • Interest expense expected to be approximately $365 million and adjusted tax rate to be approximately 19%. • Full-year CapEx unchanged at approximately $285 million, weighted to first half.
Segment performance
VisionCare: First quarter revenue of $711 million, up 5%. Consumer business grew 5%, with Lumify up 15%, consumer dry eye portfolio up 16%, iVitamins, Preservision, and Acuvite up 2%. Contact Lens revenue up 5%, led by Daily Sci-Hi and Ultra, with U.S. up 6% and international up 4%. Surgical: First quarter revenue $228 million, up 1%. Implantables up 3%, premium IOLs up 27%, consumables up 2%, equipment revenue down 4%. Pharma: Revenue $305 million, up 12%. U.S. pharma up 14%, Maibo up 33%, Zydra up 30%, international pharma up 7%.
Risks & headwinds
• Surgical business impacted by temporary factors like weather-related disruption to cataract procedures and reimbursement pressures. • Potential impact of oil and freight costs if persistently elevated. • Economic softness in certain markets like Asia-Pac and Japan could affect contact lens performance.